



**Subject Line:** Cystic Fibrosis Research Study Opportunity

***We need your help evaluating a potential new treatment option for cystic fibrosis patients!***

Eloxx Pharmaceuticals is conducting a study to understand the characteristics of an investigational drug in patients with cystic fibrosis carrying at least one G542X CFTR or phenotypically similar nonsense allele and any Class 1 or Class 2 mutation.

**Who May Participate?**

- Age 18 years or older
- Confirmed diagnosis of nonsense mutation CF with a documented G542X or phenotypically similar nonsense mutation, homozygote, or compound heterozygote with a specified mutation. For compound heterozygotes, one mutation has to be a G542X or phenotypically similar nonsense mutation, and the second mutation should be any Class 1 or Class 2 mutation.
- FEV<sub>1</sub> ≥ 40%
- Willing to complete routine study visits
- Must not have been on CFTR modulators or potentiator medications such as ivacaftor, lumacaftor, tezacaftor, and elaxacaftor within 2 months of the screening visit

There are other requirements for participation in the study. Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

**What to Expect?**

The participation in the study will last up to 15 weeks. This period includes a screening period, in which it will be determined if you are eligible to participate in the study; a treatment period, in which you will take study medication on a daily basis; and a safety follow up period, in which safety will be monitored. During the study, you will be expected to complete a minimum of nine study visits at the study site. At these visits, you will complete the following procedures including, but not limited to:

- Biospecimen collection (blood, urine, and sweat)
- Audiology assessments
- Physical examinations
- Spirometry

Study medication will be provided to you at no cost and you may be compensated for your time and travel to study centers if you choose to participate and qualify for this study.

You may find more information and participant locations at the following link:

<https://clinicaltrials.gov/ct2/show/NCT04135495?term=eloxx&draw=2&rank=1>